NASDAQ:DNLI - Denali Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Denali Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $26.05 -0.16 (-0.61 %) (As of 02/19/2020 11:31 AM ET) Add Compare Today's Range$25.62Now: $26.05▼$26.0550-Day Range$16.15MA: $22.32▼$27.9852-Week Range$14.24Now: $26.05▼$30.41Volume4,586 shsAverage Volume876,793 shsMarket Capitalization$2.50 billionP/E RatioN/ADividend YieldN/ABeta2.05 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Denali Therapeutics Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 and DNL151, which are in Phase 1 clinical trials for Parkinson's disease. It is also developing receptor interacting serine/threonine protein kinase 1 (RIPK1) product candidates, such as DNL747, a selective and brain-penetrant small molecule RIPK1 inhibitor product candidate that is in Phase 1b clinical trial for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:DNLI Previous Symbol CUSIPN/A CIK1714899 Webhttp://www.denalitherapeutics.com/ Phone650-866-8548Debt Debt-to-Equity Ratio0.16 Current Ratio10.59 Quick Ratio10.59Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$129.16 million Price / Sales19.37 Cash FlowN/A Price / Cash FlowN/A Book Value$5.76 per share Price / Book4.52Profitability EPS (Most Recent Fiscal Year)($0.39) Net Income$-36,240,000.00 Net Margins-44.73% Return on Equity-13.37% Return on Assets-10.24%Miscellaneous Employees179 Outstanding Shares96,030,000Market Cap$2.50 billion Next Earnings Date3/10/2020 (Estimated) OptionableOptionable Receive DNLI News and Ratings via Email Sign-up to receive the latest news and ratings for DNLI and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:DNLI Rates by TradingView Denali Therapeutics (NASDAQ:DNLI) Frequently Asked Questions What is Denali Therapeutics' stock symbol? Denali Therapeutics trades on the NASDAQ under the ticker symbol "DNLI." How were Denali Therapeutics' earnings last quarter? Denali Therapeutics Inc (NASDAQ:DNLI) posted its quarterly earnings results on Wednesday, November, 6th. The company reported ($0.48) EPS for the quarter, topping the consensus estimate of ($0.56) by $0.08. The business earned $13.60 million during the quarter, compared to analysts' expectations of $10.86 million. Denali Therapeutics had a negative net margin of 44.73% and a negative return on equity of 13.37%. View Denali Therapeutics' Earnings History. When is Denali Therapeutics' next earnings date? Denali Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, March 10th 2020. View Earnings Estimates for Denali Therapeutics. What price target have analysts set for DNLI? 7 analysts have issued 12-month target prices for Denali Therapeutics' stock. Their forecasts range from $19.00 to $37.00. On average, they anticipate Denali Therapeutics' share price to reach $29.57 in the next twelve months. This suggests a possible upside of 13.8% from the stock's current price. View Analyst Price Targets for Denali Therapeutics. What is the consensus analysts' recommendation for Denali Therapeutics? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Denali Therapeutics in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Denali Therapeutics. What are Wall Street analysts saying about Denali Therapeutics stock? Here are some recent quotes from research analysts about Denali Therapeutics stock: 1. According to Zacks Investment Research, "Denali Therapeutics Inc. is a biotechnology company. It focused on the discovery and development of therapies for patients with neurodegenerative disease, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis and others. Denali Therapeutics Inc. is based in SOUTH SAN FRANCISCO, United States. " (1/13/2020) 2. HC Wainwright analysts commented, "We include in our valuation given their clinical stage, and view DNL310 as a free call option at this point. Our 12-month price target of $28/share is based on an equally weighted composite of (a) $29/share, as a 35x multiple of taxed and diluted FY34 GAAP EPS of $8.62 discounted back to and (b) an NPV of $28/ share (discount rate 12.0%, growth rate 2.5%). The assumptions are in-line with the expected PE multiple and discount rate of an early development-stage biopharmaceutial company." (8/8/2019) Has Denali Therapeutics been receiving favorable news coverage? Headlines about DNLI stock have been trending somewhat negative on Wednesday, according to InfoTrie Sentiment. The research firm rates the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Denali Therapeutics earned a news sentiment score of -1.0 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the immediate future. View News Stories for Denali Therapeutics. Who are some of Denali Therapeutics' key competitors? Some companies that are related to Denali Therapeutics include Neurocrine Biosciences (NBIX), Qiagen (QGEN), BIO-TECHNE (TECH), BioNTech (BNTX), Moderna (MRNA), argenx (ARGX), Repligen (RGEN), Acceleron Pharma (XLRN), bluebird bio (BLUE), China Biologic Products (CBPO), Spark Therapeutics (ONCE), Adaptive Biotechnologies (ADPT), Ablynx (ABLYF), Crispr Therapeutics (CRSP) and Momenta Pharmaceuticals (MNTA). What other stocks do shareholders of Denali Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Denali Therapeutics investors own include Progenics Pharmaceuticals (PGNX), Kratos Defense & Security Solutions (KTOS), Intellia Therapeutics (NTLA), Sangamo Therapeutics (SGMO), Editas Medicine (EDIT), Pretium Resources (PVG), Anavex Life Sciences (AVXL), Crispr Therapeutics (CRSP), Inseego (INSG) and Pretium Resources (PVG). Who are Denali Therapeutics' key executives? Denali Therapeutics' management team includes the folowing people: Dr. Ryan J. Watts Ph.D., Co-Founder, Pres, CEO, Chief Scientific Officer & Director (Age 43)Mr. Alexander O. Schuth M.D., Co-Founder, COO & Sec. (Age 46)Dr. Marc Tessier-Lavigne, Co-Founder, Chairman of Scientific Advisory Board & Director (Age 59)Mr. Steve E. Krognes, CFO & Treasurer (Age 50)Dr. Carole Ho, Chief Medical Officer & Head of Devel. (Age 46) When did Denali Therapeutics IPO? (DNLI) raised $149 million in an initial public offering (IPO) on Friday, December 8th 2017. The company issued 8,300,000 shares at a price of $17.00-$19.00 per share. Goldman Sachs, Morgan Stanley and J.P. Morgan served as the underwriters for the IPO and Evercore ISI was co-manager. Who are Denali Therapeutics' major shareholders? Denali Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (7.90%), FMR LLC (4.29%), State Street Corp (1.67%), Casdin Capital LLC (1.30%), Bamco Inc. NY (0.99%) and Pictet Asset Management Ltd. (0.75%). Company insiders that own Denali Therapeutics stock include Alexander O Schuth, Carole Ho and Ryan J Watts. View Institutional Ownership Trends for Denali Therapeutics. Which major investors are selling Denali Therapeutics stock? DNLI stock was sold by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, FMR LLC, Citigroup Inc., Pictet Asset Management Ltd., Bamco Inc. NY, Rafferty Asset Management LLC, SG Americas Securities LLC and AQR Capital Management LLC. Company insiders that have sold Denali Therapeutics company stock in the last year include Alexander O Schuth, Carole Ho and Ryan J Watts. View Insider Buying and Selling for Denali Therapeutics. Which major investors are buying Denali Therapeutics stock? DNLI stock was purchased by a variety of institutional investors in the last quarter, including Casdin Capital LLC, Marshall Wace North America L.P., Baillie Gifford & Co., Russell Investments Group Ltd., Marshall Wace LLP, Algert Global LLC, Alpine Global Management LLC and California Public Employees Retirement System. View Insider Buying and Selling for Denali Therapeutics. How do I buy shares of Denali Therapeutics? Shares of DNLI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Denali Therapeutics' stock price today? One share of DNLI stock can currently be purchased for approximately $25.98. How big of a company is Denali Therapeutics? Denali Therapeutics has a market capitalization of $2.49 billion and generates $129.16 million in revenue each year. The company earns $-36,240,000.00 in net income (profit) each year or ($0.39) on an earnings per share basis. Denali Therapeutics employs 179 workers across the globe.View Additional Information About Denali Therapeutics. What is Denali Therapeutics' official website? The official website for Denali Therapeutics is http://www.denalitherapeutics.com/. How can I contact Denali Therapeutics? Denali Therapeutics' mailing address is 161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-866-8548. MarketBeat Community Rating for Denali Therapeutics (NASDAQ DNLI)Community Ranking: 2.4 out of 5 ( )Outperform Votes: 345 (Vote Outperform)Underperform Votes: 369 (Vote Underperform)Total Votes: 714MarketBeat's community ratings are surveys of what our community members think about Denali Therapeutics and other stocks. Vote "Outperform" if you believe DNLI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DNLI will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/19/2020 by MarketBeat.com StaffFeatured Article: How do candlesticks reflect price movement?
